41results about How to "Reduce adverse symptoms" patented technology

The invention discloses methods for identifying antibodies that reduce or prevent signaling by intact epidermal growth factor receptor (EGFR), or mutant EGFRs, such as EGFRvIII.

Disclosed are agents (e.g., peptides, polypeptides, proteins, small molecules, antibodies, and antibody fragments that target senescent cells) and methods of their use for imaging senescent cells in vivo and for treating or preventing cancer, age-related disease, tobacco-related disease, or other diseases and disorders related to or caused by cellular senescence in a mammal. The methods include administering one or more of the agents of the invention to a mammal, e.g., a human. The agents, which specifically bind to senescent cells, can be labeled with a radioactive label or a therapeutic label, e.g., a cytotoxic agent.

The present inventions features methods for treating or preventing cancer (e.g., cancer of the central nervous system) by administering a compound that inhibits PAK kinase activity and / or merlin phosphorylation to a mammal (e.g., a human). The invention also provides screening methods for identifying additional inhibitors of PAK kinase activity and / or merlin phosphorylation.

The invention features a class of 2-nitroimidazole compounds with a secondary basic nitrogen atom and a linker bearing one or more therapeutic agents, cytotoxic agents, detectable labels, or chelating groups. In particular, the invention provides 2-nitroimidazole compounds containing a cluster of boron atoms for use in boron neutron capture therapy (BNCT). The 2-nitroimidazole compounds can be used to treat hypoxic conditions, including, e.g., cancer, inflammation, and ischemia. The weakly basic 2-nitroimidazole compounds target to hypoxic tissue and provide increased tissue concentration overall.

The present invention relates to methods, compositions, and diagnostic tests for treating and diagnosing cancer and other related diseases that result in dysregulation of malic enzyme 2. In particular, the methods and compositions include combination therapy, such as with a combination of two or more ME2 inhibitors or a combination of an ME2 inhibitor and an anticancer agent.

The present invention discloses a stocking method for porcupines, and is characterized in that the stocking method comprises the steps of building a physical part, selecting a food part and selecting a feeding method. The physical part comprises a courtyard enclosed by bounding walls, the courtyard is built on an open space, and the area of the courtyard is greater than 400 square meters; the courtyard is square or circular; the bounding walls are 1.3 meters high off the ground; the bounding walls are 0.5 meters deep into the ground; the middle of the courtyard is provided with a plurality of hog houses, and a distance from an edge of each hog house to the nearest bounding wall is at least 4 meters; each hog house is built on a platform which is at least 1.2 meters high off the ground; each hog house is square or circular, and the area of each hog house is no less than 4 square meters; and no more than 3 porcupines are stocked in each hog house. Environmental conditions and food systems in the cultivation system are mutually cooperated to generate a disease control system and a disposition control system, the environmental conditions, the disease control system, the disposition control system and the food systems in the cultivation system are mutually configured, acted and balanced, behaviors and internal balance of the porcupines are remoulded, and immunity, behaviors, disposition and spleen and stomach of the porcupines are well controlled.

The present inventions features methods for treating or preventing cancer (e.g., cancer of the central nervous system) by administering a compound that inhibits PAK kinase activity and / or merlin phosphorylation to a mammal (e.g., a human). The invention also provides screening methods for identifying additional inhibitors of PAK kinase activity and / or merlin phosphorylation.

The invention discloses an ingredient for conditioning porcupines. The ingredient is composed of the following components in parts by weight: 5-6 parts of oyster shell, 30-40 parts of mung beans, 3-4 parts of lotus seed kernel, 4-5 parts of radix rehmanniae, 0.5-1 part of coptis chinensis, 3-5 parts of the root of straight ladybell, 1-2 parts of abrus herb, 10-12 parts of wax gourd, 4-5 parts of lily, 0.1-0.2 part of scaphium scaphigerum, 2-3 parts of cortex lycii radicis, 2-3 parts of longhairy antenoron herb, 4-5 parts of selfheal, 3-5 parts of radix ophiopogonis, 2-3 parts of polygonatum odoratum, 3-4 parts of lalang grass rhizome, 2-3 parts of cyrtomium fortunei, 5-7 parts of Chinese yam, 2-4 parts of polygala root, 1-2 parts of cremanthodium reniforme, 1-2 parts of herba artemisiae adamsii and 2-3 parts of soroseris gillii. The ingredient disclosed by the invention has balanced nutrition, and in addition, the food cooperates with the Chinese herbal medicines to regulate internal balance of the porcupines, so that the external behaviors of the porcupines are influenced to reduce anxious, irritable, wild and violent behaviors of the porcupines in a breeding process. Diarrhea, parasite and other diseases or symptoms are reduced further. The invention further discloses a preparation method for the ingredient.

The present invention relates to lipid compounds and uses thereof. In particular, the compounds include a class of cationic lipids having an amine moiety, such as an amino-amine or an amino-amide moiety. The lipid compounds are useful for in vivo or in vitro delivery of one or more agents (e.g., a polyanionic payload or an antisense payload, such as an RNAi agent).

The invention provides methods for the administration of an anti-CD 1 antibody for the treatment or prevention of a variety of disorders, such as autoimmune disease, viral infection, bacterial infection, parasitic infection, infection by a eukaryotic pathogen, allergy, asthma, inflammatory condition, graft versus host disease, graft rejection, immunodeficiency disease, spontaneous abortion, pregnancy, and cancer.